cyclopentane has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-David, Y; Ju, Y; Rotin, D; Zacksenhaus, E | 1 |
| Costa, SD; Ignatov, A; Ignatov, T; Ignatova, Z; Ochel, HJ; Weißenborn, C; Zenclussen, AC | 1 |
| Chen, Z; Du, J; Jiang, G; Liang, S; Liu, Q; Su, Q; Wang, H; Wei, W; Zhou, Y | 1 |
3 other study(ies) available for cyclopentane and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Cell Cycle Proteins; Cell Line, Tumor; Cyclin D1; Cyclopentanes; Drug Synergism; Elongation Factor 2 Kinase; Female; Gene Silencing; Glutaminase; Humans; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-myc; Sulfides; Thiadiazoles; Triple Negative Breast Neoplasms | 2021 |
GPER functions as a tumor suppressor in triple-negative breast cancer cells.
Topics: Apoptosis; Carcinogenesis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Quinolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; RNA, Small Interfering; Triple Negative Breast Neoplasms | 2014 |
Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Topics: Animals; Antibodies; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Movement; Cyclopentanes; Dose-Response Relationship, Drug; Female; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interleukin-6; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Neovascularization, Physiologic; NF-kappa B; Phosphorylation; Promoter Regions, Genetic; Quinolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; STAT3 Transcription Factor; Time Factors; Triple Negative Breast Neoplasms; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |